240 results about "Immunome" patented technology

The invention relates to a CACNA1A-based mental patient heart death intelligent identification system and method, the system comprises an immunohistochemical staining device, an image acquisition unit, an image analysis unit and an intelligent identification unit, the immunohistochemical staining device is used for performing CACNA1A immunohistochemical staining on formalin-fixed paraffin-embedded heart tissue slices; the image acquisition unit is used for shooting and obtaining a heart tissue CACNA1A immunohistochemical staining image; the image analysis unit is used for processing the heart tissue CACNA1A immunohistochemical staining image so as to determine a tissue staining region and image features thereof; and the intelligent identification unit outputs an identification prediction result of heart death of the mental patient according to the image features of the tissue staining region. Compared with the prior art, the mental patient heart death identification system can intelligently and accurately identify mental patient heart death.

Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus Hesperaloe. Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from Hesperaloe and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from Hesperaloe. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.

The invention relates to the field of image analysis, in particular to a colon cancer lymph node metastasis risk prediction method and system based on image analysis. The method comprises the following steps: acquiring a pathological section scanning image, carrying out layer-by-layer downsampling and feature reconstruction, and generating pathological section topological features; carrying out adaptive clustering analysis and multi-parameter fusion evaluation on the basis of the pathological section topological features to obtain independent migration evaluation values of individual tumor cells; performing tumor metastasis branch analysis according to the independent migration evaluation value, and constructing a metastasis branch path distribution diagram; extracting an immunohistochemical staining image of a patient to obtain immune cell space distribution data; and performing multi-region lymphatic metastasis simulation and metastasis risk situation prediction based on the immune cell spatial distribution data and the metastasis branch path distribution diagram to obtain a final metastasis risk assessment result. According to the method, the lymph node metastasis risk is accurately and efficiently analyzed, and the credibility of a pathological analysis result is improved.

The invention belongs to the technical field of medical diagnosis, and discloses a quantum multicolor immune digital pathological diagnosis analysis system, which comprises the following steps: acquiring high-resolution digital images of an immunohistochemical or immunofluorescence slice and a slide, and analyzing multicolor signal distribution in the images to obtain a quantum chromatographic image set; pixel-level color separation and intensity quantization are carried out on the quantum chromatographic image set, and a quantum intensity index set of each pixel is generated; performing multi-target color overlay analysis and post-translational modification protein specificity evaluation on the quantum intensity index set to construct a multi-color modification index set; identifying a single cell boundary and a multi-cell community based on the multicolor modification index set, and extracting a cell morphological parameter and a spatial adjacency relation to obtain a cell quantum analysis set; performing consistency correction and traceable recording by applying an automatic quality control mechanism, and generating a digital diagnosis report; the accuracy of accurate qualitative and quantitative analysis of immunohistochemistry and immunofluorescence is greatly improved.

The invention discloses a liquid cell product, a preparation method thereof and a preserving fluid for preparing the liquid cell product, and belongs to the technical field of immunodetection. The dendritic polymer is creatively added into the preserving fluid for preparing the liquid cell product, the cell morphology in the liquid cell product can be improved, and a thermal acceleration test proves that the preserving fluid can maintain the cell morphology in the liquid cell product for a long time. When the preservation solution is used for preparing the liquid cell quality control product for immunodetection, quality control spots with complete circles can be formed after sample application on slides made of different materials, it can be obviously judged that cells in the liquid cell quality control product are dispersed very uniformly after immunohistochemical staining, and the preservation solution has very high application value.

The invention provides an immunohistochemical method for antibody joint detection and a kit thereof, and particularly relates to the technical field of medical detection.The method comprises the steps that fresh endometrial lymph node tissue is subjected to frozen section, and a continuous section A and a continuous section B are obtained; 10% neutral buffer formalin is used for fixation; blocking by using a peroxidase blocking agent; respectively and independently dropwise adding a CK19 antibody and an MUC1 antibody on the continuous slice A and the continuous slice B; dropwise adding an HRP direct standard signal enhancer; after the DAB develops color, TBS is terminated, hematoxylin is used for redyeing, dehydration is carried out through absolute ethyl alcohol, and sheet sealing is carried out; the immunohistochemical method kit comprises a CK19 antibody, an MUC1 antibody, an HRP direct standard signal enhancer, a peroxidase blocking agent, a DAB developing solution and a TBS cleaning solution. The kit is used for rapid diagnosis of endometrial lymph node micro metastasis, the whole process only needs 15 minutes, and antigen repair is not needed.

The invention discloses a breast cancer immunohistochemical prediction method and system fused with a magnetic resonance image. The prediction method comprises the following steps: acquiring multi-sequence magnetic resonance image data of a breast cancer patient; performing preprocessing and quality control on the magnetic resonance image data; segmenting the focus of the magnetic resonance image data; segmenting the nidus habitat area of the magnetic resonance image; image omics features are extracted from the overall tumor area and the habitat sub-areas respectively; establishing a machine learning immunohistochemical prediction model; and performing breast cancer immunohistochemical prediction according to the machine learning immunohistochemical prediction model. Through multi-scale and multi-dimensional feature extraction and machine learning modeling, accurate prediction of breast cancer molecular features is realized.

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

The invention discloses application of hydrogen-rich water in preparation of a drug for treating Duchenne type muscular dystrophy, and particularly relates to the technical field of medicines.The random control experiment is adopted, homologous c57 mice serve as a normal control group, mdx mice are randomly divided into a model group and a hydrogen-rich water group, and the exercise ability is evaluated through a four-limb holding power test and a rotating bar test; detecting mouse creatine kinase by an enzyme-linked immunosorbent assay; carrying out hematoxylin-eosin, NADH-tetrazole reductase and improved Goori three-color dyeing, and carrying out cytochrome C oxidase, succinate dehydrogenase and SDH-COX combined dyeing to observe the pathological change of the skeletal muscle tissue; the invention discloses that the muscle injury condition of a Duchenne type muscular dystrophy model mouse is improved by the hydrogen-rich water through a mitochondrial protection mechanism, and the hydrogen-rich water has a relatively high application prospect and a relatively high economic value.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

The invention relates to the technical field of immunohistochemical staining, and discloses an automatic scoring method and system for immunohistochemical staining results. The method comprises the following steps: performing spectral signal intelligent deconvolution processing on a multi-immunohistochemical staining image to obtain target image data; performing multi-scale context modeling on the target image data to obtain a sub-region segmentation mask; performing depth map feature extraction on the target image data based on the subregion segmentation mask to obtain a multi-dimensional image feature vector; inputting the multi-dimensional image feature vector into a mixed deep learning recognition model to carry out marker intelligent recognition to obtain a multi-marker expression state recognition result; collaborative scoring is carried out based on the multiple marker expression state recognition result, a personalized unified scoring value is obtained, cell heterogeneity analysis is carried out on the personalized unified scoring value, and an intelligent scoring report is generated. According to the invention, the problem of spectrum crosstalk in multiple staining is effectively solved, and high-precision intelligent identification of multiple immunohistochemical markers is realized.

The present application relates to the technical field of incubation bin assembly, and aims to provide an incubation bin liquid discharge device and an immunohistochemical device to solve the technical problem of low liquid discharge efficiency of the incubation bin in the prior art, which affects incubation and reaction operation. The immunohistochemical device comprises a bottom plate and an incubation bin assembled on the bottom plate, and further comprises an incubation bin liquid discharge device assembled on the bottom plate, wherein the incubation bin liquid discharge device is connected with the incubation bin in correspondence, and the incubation bin liquid discharge device comprises a transfer bin and a liquid discharge channel connected at one end of the transfer bin, the other end of the liquid discharge channel is provided with a liquid inlet, and the liquid inlet is used for butting against a waste liquid pipe at the bottom of the incubation bin; a quick liquid discharge device is connected on the liquid discharge channel or the transfer bin, and the quick liquid discharge device is used for sucking the transfer bin to quickly suck the waste liquid in the waste liquid bin into the transfer bin.

The invention relates to a specific antibody aiming at CD228 protein and an antigen binding fragment thereof, which are used for detecting and treating various tumors, such as melanoma, mesothelioma, colorectal cancer and the like. The antibody binding fragment is helpful for diagnosis and treatment of cancers through specific binding with CD228. The invention further comprises antibody drug conjugates (ADCs) which bind a drug to an antibody through a linker, so as to improve the therapeutic effect and reduce the influence on normal cells. Meanwhile, nucleic acids encoding the antibodies or antigen-binding fragments thereof are provided to produce recombinant antibodies or fragments. Besides, the invention also provides a kit which is used for laboratory research, clinical diagnosis and treatment effect monitoring, is beneficial to determining whether tissues or cells express CD228 or not, and provides a new strategy for personalized and precise treatment of cancers.

The present application provides a CD4 helper T cell epitope fusion peptide, its encoding nucleic acid and an immune composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope. The epitope fusion peptide provided by the present application can greatly improve the cellular immune response level of the target immunogen, especially a weak immunogen, and is an effective means to overcome the immune system's immune tolerance to antigens, especially tumor antigens or infection-related antigens, and is suitable for efficiently enhancing the efficacy of vaccines.

The application discloses a B cell immune repertoire antibody sequence feature analysis and specific screening method and related equipment, which can be applied to the technical field of data processing. According to the application, after the antibody sequencing sequence is subjected to germ line comparison and recognition to obtain corresponding first sequencing Fv sequence and germ line Fv sequence, the first sequencing Fv sequence is subjected to gene integrity filtering and structure integrity filtering, clonotype division and root node sequence reconstruction to obtain a second clonotype collection, and then a first lineage forest is constructed, and according to the second sequencing Fv sequence, the second clonotype collection or the first lineage forest, sequence feature analysis in multiple dimensions is carried out, so that the antibody sequence features can be analyzed from multiple dimensions such as sequence quality, sequence abundance, mutation degree, mutation preference and aggregation degree, the filtered BCR sequence has high affinity, and according to the sequence feature analysis results in multiple dimensions or the first lineage forest, a visualized graph is generated, so that relevant personnel can view the sequence features.

The invention provides a method for carrying out multi-term immunohistochemical staining by using a single tissue slice, which is characterized by comprising the following steps: S1, selecting and preparing a tissue slice to be detected, S2, analyzing pathological tissues and related information of an HE tissue slice, S3, marking, transferring, correcting and punching staining through holes of the HE tissue slice and the tissue slice to be detected, S4, preparing before immunohistochemical staining, and S5, carrying out multi-term immunohistochemical staining by using a single tissue slice. Removing the protective film on the bottom surface of the perforated transparent adhesive sticker, bonding the bottom surface of the transparent adhesive sticker with the wax mask tissues of the to-be-detected tissue slice, exposing the wax mask tissues of the to-be-detected tissue slice at the bottoms of the dyeing through holes corresponding to the transparent adhesive sticker respectively, and removing the protective film on the surface of the transparent adhesive sticker to obtain the to-be-detected tissue slice. And opening or closing the corresponding dyeing through holes by using the silica gel nail covers to form the to-be-detected tissue sample sheet with a plurality of dyeing holes. And more comprehensive detection results of a plurality of items can be obtained on only one tissue slice, so that the application range of immunohistochemical detection is expanded, the immunohistochemical detection time is shortened, the working efficiency is improved, and the detection cost is reduced.

The application relates to the technical field of immunohistochemical instruments, in particular to an automatic detection immunohistochemical instrument based on a negative pressure channel environment, which comprises an immunohistochemical instrument equipment main body, the inside of the immunohistochemical instrument equipment main body is provided with a slide storage compartment and a reagent storage compartment, beneficial effects are that: through corresponding installation of slide sealing and fixing covers and reagent sealing cover plates on a slide loading assembly and a reagent disc, separate loading and rotary conveying of reagents and slides are realized, the sampling needle outer tube body is matched with sampling needle positioning tubes one and two on the slide sealing and fixing covers and the reagent sealing cover plates to form precise positioning, in the positioning and releasing lifting process, a hemispherical support and a spherical sampling tube form a movement action to make the spherical sampling tube form a negative pressure, liquid leakage is avoided, the whole detection process relies on slide recognition equipment and reagent recognition equipment to independently recognize slides and reagents, the same reagent is added dropwise to each group of multiple slides, the same reagent is added dropwise in the same round, the sample adding needle does not produce liquid drops and leakage.

The invention discloses a sequencing method of an immune repertoire, which comprises the following steps: 1) constructing a cDNA library of a sample, the cDNA in the cDNA library being connected with the position information of the cDNA on the sample; 2) enriching cDNA of TCR and / or BCR genes in the cDNA library in a targeted manner to obtain an immune repertoire of the sample; and (3) sequencing the immune repertoire. According to the method disclosed by the invention, targeted enrichment and high-throughput sequencing of TCR and / or BCR sequences are innovatively realized, and gene expression information and spatial position information of each cell in a space are detected at the same time.

This invention discloses an anti-MSLN antibody and its applications. The anti-MSLN antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3. The amino acid sequences of HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NO:7, 8, and 9, respectively; and the amino acid sequences of LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NO:4, 5, and 6, respectively. The antibody provided by this invention has good affinity and specificity for MSLN antigens, effectively detecting target proteins in cells overexpressing MSLN. It can also be widely used as a core ingredient in the development of high-sensitivity MSLN detection kits such as ELISA, Western blotting, and immunohistochemistry.

The invention discloses a toxoplasma gondii double-gene deletion attenuated vaccine strain as well as a construction method and application thereof. The toxoplasma gondii double-gene deletion attenuated vaccine strain is constructed by deleting a ku80 gene and a CDC14 gene on the basis of a toxoplasma gondii type II PLK strain, and is named as PLK [delta] TgKu80 [delta] TgCDC14 ([delta] CDC14 for short), and experimental results show that the pathogenicity of the strain is remarkably reduced after the CDC14 gene is knocked out. In order to further explore the immune protection effect on toxoplasma gondii acute infection mice, secondary acute infection is carried out on mice immunized with delta CDC14 strains, and the result shows that compared with non-immunized group mice, no immunized mice die within 30 days, and all non-immunized mice die within 13 days. Therefore, the double-gene deletion attenuated vaccine strain has the potential of being used as a vaccine, and an effective technical means is provided for preventing toxoplasma gondii infection.

This invention provides a clinical trial matching system and method for tumor patients based on a large language model and OCR technology, applicable to the field of medical data processing. This application parses clinical data and trial information, processes unstructured text, and generates structured clinical feature data through contextual association analysis; extracts key data and performs double verification and correction to generate supplementary structured data information; enhances the structured clinical feature data and supplementary information based on a multimodal processing pipeline module, extracts image quantification indicators, analyzes immunohistochemical results, and generates a comprehensive matching score; compares patient features with inclusion and exclusion conditions item by item through a rule engine and semantic similarity calculation to generate preliminary matching results; corrects misjudgments of marginal cases through context-aware multi-round reasoning, and adjusts the ranking based on clinical trial priority weights to generate an optimized clinical trial matching list; and generates a clinical trial matching report based on the above data.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The application provides a construction method of a humanized keloid mouse model, comprising the following steps: BAC plasmid construction and preparation; superovulation of experimental mice and collection of zygotes; pronuclear microinjection of zygotes; post-injection embryo transplantation; genotype identification; breeding and genetic analysis; and verification of construction results of the humanized immune system by immunohistochemistry and immunofluorescence. In the application, peripheral blood mononuclear cells treated by sCD27 and skin around keloids (homologous cells and tissues) are transplanted into NSG-MHC-DKO immune-deficient mice with overexpression of CD70 genes, so that HLA rejection of different homologous immune cells and tissues can be avoided, the internal microenvironment of keloids and the interaction between the internal microenvironment and the immune system can be restored to the maximum extent, and the influence of immune factors on the occurrence and development of keloids can be realized in vitro. The application first discovers and verifies that the activation of the CD27-CD70 axis can promote the occurrence and development of keloids, and provides a suitable animal model for the research and development of anti-keloid drugs, especially immunotherapy.

The present application relates to the antibody of phorbolylated isocitrate dehydrogenase 1 and its preparation method and purpose, and specifically provides a polyclonal antibody, the polyclonal antibody is obtained by immunizing animals with the antigen epitope peptide of IDH1 phorbolylated, the specific site of the antigen epitope peptide is phorbolylated, and high-titer antibodies can be prepared, the phorbolylated modification of IDH1 in clinical specimens can be recognized with high specificity, and the polyclonal antibody can be used for the research of cell / tissue specimen immunoblotting and immunohistochemical method and the diagnosis of IDH1 related diseases.

This invention discloses a virtual immunohistochemical staining method and system based on relation generative adversarial networks (GANs) and sequence slide data, comprising the following steps: Step S1, constructing a sequence slide dataset, wherein each H&E-stained slide is followed by three consecutive Ki67-stained slides; Step S2, constructing a relation generative adversarial network (GAN) model, the model comprising two ResNet generators and two relation discriminators, used to train and evaluate the credibility of the sequence relationship between image pairs; Step S3, performing two-stage training on the relation generative adversarial network model, namely, basic style pre-training and Z-axis alignment relation adaptation. This invention fundamentally solves the Z-axis alignment problem, resulting in higher image fidelity and pathological accuracy, significantly improving clinical application value, and providing new research resources and evaluation paradigms.

Devices and methods are described for utilizing occlusive dressings in combination with topical medicaments to enhance the efficacy of vaccines. The occlusive dressing delivers a defined dose of a topical medicament that enhances the immune system responsiveness of the vaccine to the vaccination site and provides a barrier that maintains the topical medicament layer on the skin for a desired period of time while also providing a port through which the immunization composition can be administered. In some embodiments, the occlusive dressing comprises a wound dressing used to cover the injection site after vaccination.

The invention provides an immune senescence detection marker Granzyme B, an immune senescence regulation and control target BHLHE40 and application, and belongs to the technical field of biological medicine. The invention discloses the continuous up-regulation characteristic of the GZMB in the senescence process of the primate immune system for the first time, defines the consistent expression trend of the GZMB in various immune tissues, and determines that the GZMB can be used as a reliable molecular marker for reflecting the overall immune senescence state. The invention also discloses a key regulatory pathway for immune aging, and finds that the GZMB can activate an NF-kappa B signal pathway, up-regulate inflammation and aging related genes such as CDKN1A, NFKBIA and S100A4, and promote functional degradation of immune cells; it is identified that the transcription factor BHLHE40 is a key upstream regulation factor of GZMB, expression of GZMB and downstream senescence genes can be remarkably reduced by knocking down BHLHE40, and the core effect of the BHLHE40-GZMB pathway in immune senescence is clarified.

The invention discloses an antigen binding fragment of an anti-human PRAME protein, a monoclonal antibody as well as preparation and application of the monoclonal antibody. CDR1 of a heavy chain variable region of the antigen binding fragment of the anti-human PRAME protein comprises an amino acid sequence as shown in SEQ ID NO.1, CDR2 comprises an amino acid sequence as shown in SEQ ID NO.2, and CDR3 comprises an amino acid sequence as shown in SEQ ID NO.3; cDR1 of a light chain variable region of the antigen binding fragment of the anti-human PRAME protein comprises an amino acid sequence as shown in SEQ ID NO.4, CDR2 of the light chain variable region of the antigen binding fragment of the anti-human PRAME protein comprises an amino acid sequence as shown in SEQ ID NO.5, and CDR3 of the light chain variable region of the antigen binding fragment of the anti-human PRAME protein comprises an amino acid sequence as shown in SEQ ID NO.6. The monoclonal antibody provided by the invention has high specificity and low cross reactivity, can efficiently and specifically recognize natural and denatured PRAME proteins, and is suitable for immunological detection, especially immunohistochemical detection.

This application relates to the field of tumor metabolic biomarker detection technology, and discloses a method for detecting glucose metabolism biomarkers in esophageal cancer based on VAV2-related molecular characteristics. The method includes: performing immunohistochemical staining on esophageal cancer tissue samples to obtain VAV2, EIF3F, MTA1, and HIF-1α protein expression sections; scoring the immunoreaction of each section; calculating a comprehensive glucose metabolism phenotype score based on the molecular hierarchy of the VAV2-EIF3F-MTA1 / HIF-1α glucose metabolism regulatory pathway; and classifying the samples into high-glycolytic, moderate-glycolytic, and low-glycolytic types according to the comprehensive score. This application improves the accuracy and stability of glucose metabolism phenotype discrimination in esophageal cancer.

The invention relates to the technical field of immunohistochemical staining image quantitative analysis, in particular to an immunohistochemical staining image quantitative analysis method and system, and the method comprises the following steps: S1, obtaining a digital image of an immunohistochemical staining section; and S2, carrying out color deconvolution processing on the digital image, and decomposing the digital image into an exclusive channel image corresponding to at least one target coloring agent and a background channel image. According to the method, color deconvolution is realized through a non-negative matrix factorization algorithm, target coloring agent signals and background and other dyeing signals in the composite dyeing image are accurately split, and the problem that dyeing components of an existing system are not thoroughly separated is solved; through combination of a Mask R-CNN deep learning network and multi-mode adaptive parameters, positive and negative cells in different dyeing modes can be accurately identified, and multiple scenes such as nuclear dyeing, membrane dyeing and slurry dyeing can be adapted.